drugset / Trial / NCT03288571
Use of Wharton Jelly in Diabetic Nephropathy
Phase 1/2
Unknown
20 enrolled
Sophia Al-Adwan
An-Najah National University · collabJordan University of Science and Technology · collab
NaSingle-groupOpen-labelTreatment
Summary
Wharton Jelly derived Mesenchymal stem cells will be injected in the renal parenchyma of patients with Diabetic Nephropathy
Timeline
- Start
- 2019-11
- Primary completion
- 2020-12
- Completion
- 2021-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Wharton Jelly Mesenchymal stem cells | Cell therapy | 3 ml | Other |